Platelet-dependent and procoagulant mechanisms in arterial thrombosis

International Journal of Cardiology

Volumn 68, Issue SUPPL. 1, 1999, Pages

  Eisenberg, Paul R ^a,c   Ghigliotti, Giorgio ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Arterial thrombosis; Coagulation dependent mechanisms; Initiation; Interaction; Platelets; Progression

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; PROCOAGULANT; THROMBOPLASTIN;

ARTERY THROMBOSIS; ARTICLE; CORONARY ARTERY THROMBOSIS; DRUG MECHANISM; ENDOTHELIUM INJURY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 0033541460     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00284-8     Document Type: Article

References (53)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
2. Falk E. Unstable angina with fatal outcome; dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
3. The EPIC Investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 FAb fragment directed against the platelet glycoprotein IIb/IIIa receptor. N Engl J Med 1994;330:956-61.
4. Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689-96.
6. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989;79:657-65.
7. Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Thromb Haemost 1994;71(4):511-6.
8. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85(2):805-15.
9. GUSTO investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335(11):775-82.
10. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333(12):764-9.
11. Eisenberg PR, Lee J, Miletich JP. Importance of platelets in arterial clot-associated procoagulant activity. Circulation 1995;92:803.
12. Ghigliotti G, Waissbluth AR, Speidel C, Abendschein DR, Eisenberg PR. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol 1998;18(2):250-7.
13. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16(Suppl L):11-5.
14. Sixma JJ, de Groot PG. Regulation of platelet adhesion to the vessel wall. Ann NY Acad Sci 1994;714:90-9.
15. Hawiger J. Adhesive interactions of platelets and their blockade. Ann NY Acad Sci 1991;614:270-8.
16. Kirchhofer D, Tschopp TB, Steiner B, Baumgartner HR. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995;86(10):3815-22.
17. Ruggeri ZM. The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces [Review]. Thromb Haemost 1995;74(1):460-3.
18. Sakariassen KS, Fressinaud E, Girma JP, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann NY Acad Sci 1987;516:52-65.
19. Ikeda Y, Handa M, Kawano K et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991;87(4):1234-40.
20. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and Bernard-Soulier syndrome. J Lab Clin Med 1978;92:750-64.
21. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84(2):289-97.
22. Kleiman NS, Raizner AE, Jordan R et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26(7):1665-71.
23. Speidel CM, Thornton JD, Meng YY, Eisenberg PR, Edgington TS, Abendschein DR. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Artery Dis 1996;7(1):57-62.
24. Barstad RM, Hamers MJAG, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol 1995;15:11-6.
25. Marmur JD, Rossikhina M, Guha A et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993;91:2253-9.
26. Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies performed using in vivo and in vitro models. Am J Cardiol 1993;72(8):55C-60C.
27. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-43.
28. Bach RR. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988;23:339-67.
29. Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. J Biol Chem 1983;258:13970-7.
30. Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem 1990;265(28):17132-171340.
31. Mann KG. The coagulation explosion. Ann NY Acad Sci 1994;714:265-9.
32. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995;75(6):12B-7B.
33. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991;78(2):423-34.
34. Kotze HF, Lamprecht S, Badenhorst PN. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Blood 1995;85(11):3158-63.
35. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988;85:3184-8.
36. Cadroy Y, Hanson SR, Kelly AB et al. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994;83(11):3218-24.
37. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982;257:859-64.
38. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993;9:1-26.
39. Dahlback B. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995;73(5):739-42.
40. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332(14):912-7.
41. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984;74:1-6.
42. Reverter JC, Bèguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996;98:863-74.
43. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94(9):2064-71.
44. Serruys PW, Herrman JR, Simon R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
45. Zoldhelyi P, Bichler J, Owen WG et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994;90(6):2671-8.
46. Scharfstein JS, Abendschein DR, Eisenberg PR et al. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. Am J Cardiol 1996;78(5):503-10.
47. Lynch Jr. JJ, Sitko GR, Mellott MJ et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994;28(1):78-85.
48. Lynch Jr. JJ, Sitko GR, Lehman ED, Vlasuk GP. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995;74(2):640-5.
49. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996;16(10):1285-91.
50. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. J Am Med Assoc 1997;278(6):479-84.
51. CAPTURE group. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349(9063):1429-35.
52. The Prism Plus Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
53. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998;339:436-43.